Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • ASCI Milestone Awards
    • Video Abstracts
    • Conversations with Giants in Medicine
  • Reviews
    • View all reviews ...
    • Neurodegeneration (Mar 2026)
    • Clinical innovation and scientific progress in GLP-1 medicine (Nov 2025)
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • ASCI Milestone Awards
  • Video Abstracts
  • Conversations with Giants in Medicine
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Top
  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal
  • Top
  • Abstract
  • Supplemental material
  • Version history
  • Article usage
  • Citations to this article

Advertisement

ResearchIn-Press PreviewGeneticsNeuroscience Open Access | 10.1172/JCI200890

Four subtypes of disease-causing missense mutations underlie pathogenic protein interactions in neurodegenerative VPS13A disease

Xing Lin,1 Yuta Ryoden,1 Chigure Suzuki,2 Hiroyuki Ishikawa,1 Takaharu Sakuragi,1 Yasuo Uchiyama,3 and Shigekazu Nagata1

1Laboratory of Biochemistry and Immunology, The University of Osaka, Suita, Japan

2Department of Cellular and Molecular Pharmacology, Juntendo University, Tokyo, Japan

3Department of Cellular and Neuropathology, Juntendo University, Tokyo, Japan

Find articles by Lin, X. in: PubMed | Google Scholar

1Laboratory of Biochemistry and Immunology, The University of Osaka, Suita, Japan

2Department of Cellular and Molecular Pharmacology, Juntendo University, Tokyo, Japan

3Department of Cellular and Neuropathology, Juntendo University, Tokyo, Japan

Find articles by Ryoden, Y. in: PubMed | Google Scholar

1Laboratory of Biochemistry and Immunology, The University of Osaka, Suita, Japan

2Department of Cellular and Molecular Pharmacology, Juntendo University, Tokyo, Japan

3Department of Cellular and Neuropathology, Juntendo University, Tokyo, Japan

Find articles by Suzuki, C. in: PubMed | Google Scholar

1Laboratory of Biochemistry and Immunology, The University of Osaka, Suita, Japan

2Department of Cellular and Molecular Pharmacology, Juntendo University, Tokyo, Japan

3Department of Cellular and Neuropathology, Juntendo University, Tokyo, Japan

Find articles by Ishikawa, H. in: PubMed | Google Scholar

1Laboratory of Biochemistry and Immunology, The University of Osaka, Suita, Japan

2Department of Cellular and Molecular Pharmacology, Juntendo University, Tokyo, Japan

3Department of Cellular and Neuropathology, Juntendo University, Tokyo, Japan

Find articles by Sakuragi, T. in: PubMed | Google Scholar

1Laboratory of Biochemistry and Immunology, The University of Osaka, Suita, Japan

2Department of Cellular and Molecular Pharmacology, Juntendo University, Tokyo, Japan

3Department of Cellular and Neuropathology, Juntendo University, Tokyo, Japan

Find articles by Uchiyama, Y. in: PubMed | Google Scholar

1Laboratory of Biochemistry and Immunology, The University of Osaka, Suita, Japan

2Department of Cellular and Molecular Pharmacology, Juntendo University, Tokyo, Japan

3Department of Cellular and Neuropathology, Juntendo University, Tokyo, Japan

Find articles by Nagata, S. in: PubMed | Google Scholar |

Published March 24, 2026 - More info

J Clin Invest. https://doi.org/10.1172/JCI200890.
Copyright © 2026, Lin et al. This work is licensed under the Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
Published March 24, 2026 - Version history
View PDF
Abstract

VPS13A is an intracellular lipid transfer protein comprising over 3,000 amino acids. Mutations in human VPS13A cause VPS13A disease, a neurodegenerative disorder that affects movement and cognition. VPS13A forms a complex with the membrane protein XK to mediate ATP-induced phospholipid scrambling in the plasma membrane. Here, we established a mouse cell system expressing full-length mouse VPS13A and examined its interaction with XK. Mutational analysis revealed that VPS13A binds to XK through a C-terminal β-strand that interacts with a β-hairpin in the central region of XK, an interaction essential for scramblase activity. The XK paralog XKR2, which contains a similar β-hairpin structure, also associates with VPS13A and supports phospholipid scrambling. We analyzed ten mouse VPS13A variants corresponding to patient mutations and classified them into four groups: (1) L67P, I90K, and W2453R, which showed reduced expression; (2) A1091P and M3080R, which were normally expressed but lacked scramblase activity; (3) S1446P, Q2689H, Y2713C, and R3084H, which modestly impaired expression or activity; and (4) I2763R, which altered cell size, and disrupted ER independently of XK. These findings define the VPS13A–XK interaction interface, clarify the functional impact of disease-causing mutations, and reveal an unexpected gain-of-function mutation of a VPS13A variant.

Graphical Abstract
graphical abstract
Supplemental material

View Unedited blot and gel images

View

Version history
  • Version 1 (March 24, 2026): In-Press Preview

Article tools

  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal

Metrics

  • Article usage
  • Citations to this article

Go to

  • Top
  • Abstract
  • Supplemental material
  • Version history
Advertisement
Advertisement

Copyright © 2026 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts